IMPACT Medicom IMPACT Medicom

In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies.

Our Guest:
Dr. Barbara Melosky
Dr Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group and is creator and chair of the British Columbia Lung Cancer Biobank. 

This podcast episode was sponsored by Sanofi Aventis Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer. 

Our Guests:

Dr. Christine Brezden-Masley
Dr.  Brezden-Masley is a Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health System in Toronto, Canada.

Dr. Catherine Streutker
Dr.  Streutker is a Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant.

Our guest:
Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease.

Note:
The faculty for this program had full editorial control of the content.

The following program was funded by Sanofi.

Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s. 

Our Guest:
Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, Nova Scotia. He is currently a Professor of Surgery at Dalhousie University. His expertise and clinical interest includes rhinoplasty/nasal surgery, eyelid surgery, management of facial paralysis, facial skin cancer, facial reconstruction, and surgery of the aging face.

Note:
The faculty for this program had full editorial control of the content.

The following program was funded by Sanofi.

Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.

Our Guests:
Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, Canada

Dr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, Canada

Note: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.html

This podcast episode was sponsored by Sanofi-Aventis Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss  updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. 
Our Guest:
Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.

Note: The ALPINE trial is published in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.

This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com